Technology Platforms » Intellectual Property

Intellectual Property

VIRxSYS has developed an extensive portfolio of intellectual property which is protected by a combination of patents, pending patent applications, trade secrets, and trademark law.  The issued patents, pending applications and trade secrets cover lentiviral vectors, cell processing and RNA trans-splicing technology.

The Company currently has 11 issued U.S. patents and 45 issued foreign patents with claims relating to, among other things, lentiviral vectors and related manufacturing methods. In addition the Company has approximately 110 foreign and domestic patent applications currently undergoing prosecution.  The Company also has a patent portfolio related to its SMaRT™ RNA technologies. This patent portfolio contains 4 issued U.S. patents covering the core technology and one patent recently issued covering the use of PTMs for a particular use. This portfolio also contains 15 foreign patents, 10 pending U.S. applications, and approximately 40 foreign pending applications worldwide.  Below is a list of the Company’s issued patents in the United States.

Lentiviral Vector Related Patents

Issue Date    Patent          Title

Mar '99            5,885,806      Methods To Prepare Conditionally Replicating Viral Vectors
Mar '99            5,888,767      Method Of Using Conditionally Replicating Viral Vectors To Express A Gene
Sep '00            6,114,141      Methods To Express Genes From Viral Vectors
Jan '01             6,168,953      Genetic Antiviral Agents And Methods For Their Use
Mar '01            6,207,426       Conditionally Replicating Viral Vectors And Their Use
May '01           6,232,120        Methods To Inhibit Replication Of Infective Virus
Jun '02            6,410,257        Methods To Determine The Function Of A Gene Using Conditionally Replicating Viral Vectors
Dec '02           6,498,033         HIV-Based Vectors That Express Any Heterologous Genetic Payload From The HIV-LTR Promoter
Sep '03           6,627,442         Methods For Stable Transduction Of Cells With HIV-Derived Viral Vectors
Dec '04           6,835,568         Regulated Nucleic Acid And Expression System
Sep '08           7,427,474         High-Throughput Methods for Identifying Gene Function Using Lentiviral Vectors

SMaRT™ RNA Related Patents

Issue Date          Patent Number        Title

January 2000        6,013,487                   Chimeric RNA Molecules Generated By Trans-Splicing
July 2000               6,083,702                   Methods And Compositions For Use In Spliceosome Mediated RNA Trans-Splicing
August 2001          6,280,978                  Methods And Compositions For Use In Spliceosome Mediated RNA Trans-Splicing
August 2006          7,094,399                  Use Of Spliceosome Mediated RNA Trans-Splicing To Confer Cell Selective Replication To Adenoviruses
July 15, 2008          7,399,753                 Trans-Splicing Mediated Photodynamic Therapy

As mentioned above, in addition to the Company’s patent estate, VIRxSYS has extensive intellectual property which is protected by well established trade secret law.  Such intellectual property includes extensive manufacturing processes and techniques which have not been published or patented.  These trade secrets, which have been accumulated, advanced and refined with years of clinical manufacturing experience, represent an important component in the Company’s intellectual property and competitive advantage.

© 2009 VIRxSYS. All rights reserved. Legal Notice
Site powered by True Presence.

"VIRxSYS has a powerful portfolio of technology in lentiviral vectors and cell process manufacturing which we protect with a combination of patents and trade secret laws."
Gary McGarrity, VIRxSYS EVP Scientific and Clinical Affairs